Functional Ingredients and Claims for Skincare in United States

FDA scrutiny is tightening around skincare claims in the United States

For skincare brands planning market entry or global expansion into the United States, the most important development in 2026 is not a single blockbuster rule change. It is the steady rise in enforcement pressure around product claims, ingredient positioning, and the line between a cosmetic and a drug. The US Food and Drug Administration continues to focus on claims that imply treatment, prevention, repair, or physiological change, while retailers, Amazon compliance teams, and class-action lawyers are adding their own filters. The result is simple: a skincare formula that is commercially successful in one market can become a regulatory compliance problem the moment it is translated for US consumers.

That matters because US skincare growth remains attractive, but the route to scale is narrow. A serum marketed abroad as “anti-inflammatory,” “heals eczema,” or “repairs the skin barrier at the cellular level” may trigger drug classification concerns in the US even if the ingredient list itself is acceptable in a cosmetic. For founders and marketing directors, the commercial implication is immediate. Your claims architecture now affects retailer acceptance, paid media approvals, conversion rates, insurance exposure, and the cost of reformulation or relabeling after launch.

The strategic takeaway for brands is that “functional ingredient” storytelling must be built from the claim backward, not just from the formula forward. In the US, ingredients do not automatically grant permission to make efficacy claims. Niacinamide, peptides, salicylic acid, colloidal oatmeal, probiotics, retinol, and vitamin C each sit in different practical risk categories depending on concentration, context, and wording. Brands entering the market need a disciplined benchmark of competitor claims, a realistic competitive analysis of what major retailers allow, and a label review process before creative is finalized.

What is actually allowed: the US distinction between cosmetic and drug claims

Under the Federal Food, Drug, and Cosmetic Act, most skincare products in the US are regulated as cosmetics unless they are intended to affect the structure or function of the body or to diagnose, cure, mitigate, treat, or prevent disease. In practice, this means claims such as “moisturizes,” “smooths,” “improves appearance of dullness,” “visibly reduces the look of fine lines,” and “cleanses pores” are generally positioned as cosmetic claims. By contrast, “treats acne,” “reduces inflammation,” “restores collagen production,” “heals rosacea,” or “repairs damaged skin cells” may move a product into drug territory or invite enforcement attention.

There is a common misconception among overseas brands that softening language solves everything. It does not. Phrases like “supports healing,” “targets eczema-prone skin,” or “works on inflammatory pathways” can still create regulatory risk if the implied intended use is therapeutic. The FDA also looks beyond the front label. Product pages, social captions, influencer scripts, customer reviews featured in brand-controlled channels, and before-and-after images all contribute to the overall intended use impression. That is why a US launch plan should treat claims review as an omnichannel exercise, not a packaging-only task.

There are also products that may qualify under over-the-counter monographs, such as acne treatments using permitted active ingredients and conditions of use. But brands should not assume this creates flexibility everywhere. If a formula contains salicylic acid, sulfur, or benzoyl peroxide and the product is marketed to treat acne, drug rules, facts panel requirements, and other obligations may apply. The same is true for sunscreens, which are regulated as OTC drugs in the US, not standard cosmetics. Many international skincare companies underestimate the operational burden this creates for formulation, testing, packaging, and retailer compliance.

• Generally lower-risk cosmetic wording: hydrates, softens, brightens appearance, smooths texture, refreshes, cleanses, removes makeup, improves the look of dryness.
• Higher-risk wording: heals, repairs skin structure, stimulates collagen, anti-inflammatory, antimicrobial treatment, restores barrier function at a biological level, treats acne, relieves eczema.
• Special caution categories: sunscreen, acne, dandruff/scalp treatment, hyperpigmentation treatment, eczema/psoriasis language, wound or scar healing claims.

Functional ingredients under the microscope: what brands can say, and what they should avoid

The pressure point in 2026 is not whether an ingredient is trendy; it is whether brands can translate ingredient function into compliant consumer language. Take niacinamide. In the US skincare market, niacinamide is widely used in serums, moisturizers, and tone-evening products. Cosmetic-friendly claims often include “helps improve the appearance of uneven tone,” “supports a smoother-looking complexion,” or “helps reduce the look of excess oil.” Risk rises when brands claim it “treats melasma,” “reduces inflammation,” or “repairs the skin barrier” as a physiological certainty.

Peptides are another area where copy frequently overreaches. A peptide cream can generally talk about firmer-looking skin, improved appearance of fine lines, or smoother texture. Trouble begins when marketing claims “rebuilds collagen,” “signals skin regeneration,” or “restores dermal structure.” In a US regulatory context, language that implies structural change to the body can be problematic even if it is common in premium beauty marketing outside the country. The commercial irony is that some of the most sophisticated-sounding claims are often the least useful for a compliant market positioning strategy.

Retinol and retinal products require especially careful messaging. “Improves the appearance of wrinkles” is very different from “reverses photoaging” or “repairs sun damage.” Likewise, vitamin C can be framed around brightness, radiance, and visible tone improvement, but “eliminates pigmentation disorders” is a red flag. Colloidal oatmeal may appear straightforward, yet “soothes dry, sensitive skin” is safer than “treats eczema flare-ups” unless the product is being marketed under an applicable drug framework. And with microbiome-themed products, “balances skin” may be easier to defend than “restores healthy bacterial function” or “fights pathogenic microbes.”

Why claims compliance now affects pricing, retail acceptance, and conversion

Claims are not just a legal review issue. They shape pricing, shelf placement, and the brand story that justifies premiumization. In the US, brands often assume stronger science language supports higher pricing. Sometimes it does, but if those claims trigger retailer edits, ad disapprovals, or product detail page removals, the economics reverse quickly. A $58 serum positioned with elegant, compliant efficacy language may convert better over time than a $62 serum that repeatedly loses paid media traction because the copy reads like an unapproved drug claim.

Retailers and marketplaces each apply their own standards on top of FDA risk. Sephora, Ulta, Credo, Target, Walmart Marketplace, and Amazon all create practical filters on what appears in titles, bullets, imagery, and backend content. Amazon is especially relevant because many overseas skincare brands use it as a first-step market entry channel. Listings that mention disease terms, exaggerated treatment outcomes, or unsupported performance claims can be suppressed even when the product remains legally sold elsewhere. That turns claims review into a sales enablement function.

This is where strong competitive analysis matters. The question is not only “What can we legally say?” but also “What are the best-performing US brands actually saying at our price point?” In a premium hydration category, for example, the winning message may be “deeply replenishes moisture for a plumper look” rather than “restores trans-epidermal barrier function.” In acne-adjacent cleansing, the answer may involve launching a cosmetic cleanser first and reserving treatment language for a later OTC strategy. If your team is still translating claims from your home market line by line, you are likely overcomplicating the wrong parts of the launch.

For brands needing a fast read on how their positioning stacks up, a US Market Snapshot can help identify current category norms, channel pricing bands, and claims patterns before expensive packaging or creative decisions are locked in. For deeper decision-making, a full US Launch Report is more useful when the brief includes not just size-of-prize data, but benchmarked claim language, channel fit, and likely friction points by retailer.

How smart brands build a US claims strategy before launch

The best-performing entrants to the US skincare market usually build claims in four layers: formula reality, legal tolerance, consumer readability, and channel compatibility. Start with the ingredient deck and ask what the product can credibly support without stretching into structure/function or disease language. Then pressure-test those claims against FDA logic, retailer content policies, and litigation-sensitive words such as “non-toxic,” “clinical,” “dermatologist approved,” “hypoallergenic,” or “clean” unless substantiation is robust.

Next, refine the message so it still sells. Compliant language does not have to be bland. “Visibly calms the look of redness caused by dryness” is commercially stronger and less risky than “anti-inflammatory treatment.” “Leaves skin looking clearer and more balanced” may be a practical alternative to “fights acne-causing bacteria” for a cosmetic formula. The point is not to remove efficacy; it is to express efficacy through appearance, feel, and consumer-perceivable outcomes rather than biological intervention.

Third, treat substantiation as part of brand operations. If you use claims such as “clinically tested,” “97% saw smoother skin,” or “safe for sensitive skin,” maintain accessible support files. In the US, plaintiff firms and regulators both care about whether claims are truthful and not misleading. Internal discipline around claim support is now a growth lever, not just a legal expense. An AI Label Compliance Analysis can help identify problematic phrasing early, especially when a global team is repurposing artwork or PDP copy across markets.

1. Audit all touchpoints: label, carton, product page, social ads, influencer briefing notes, and email copy.
2. Map claims by risk tier: safe cosmetic, review-needed, and likely drug-triggering.
3. Benchmark competitors: compare wording used by top US brands in your price band and channel.
4. Align pricing with claim style: premium products need sophisticated but compliant benefit language.
5. Review marketplace rules: especially for Amazon, where suppression risk can hit sales fast.
6. Store substantiation: keep consumer perception tests, ingredient support, and clinical summaries organized.

Where international skincare brands most often get caught out in the United States

The first mistake is assuming an ingredient that is acceptable in a cosmetic automatically supports quasi-medical marketing. That is not how the US system works. The second is failing to localize claims culture. Some regions tolerate more mechanistic wording on packaging; the US often does not, especially when the language implies treatment or structural change. Third, brands underestimate how fragmented enforcement is. FDA action is one risk, but so are state-level consumer claims, competitor challenges, platform restrictions, and retailer review teams.

A common failure point is the acne-adjacent product set: clarifying toners, blemish serums, spot products, and barrier creams for breakout-prone skin. If salicylic acid appears in the formula, or if the copy repeatedly uses “acne,” “breakouts treatment,” or “prevents pimples,” the product may need to meet OTC drug expectations. Another problem area is sensitivity and redness. “For reactive-looking skin” can be manageable; “for rosacea relief” is not a routine cosmetic claim. The same caution applies to hyperpigmentation. “Improves the look of post-blemish marks” is different from “treats post-inflammatory hyperpigmentation.”

Even luxury brands make mistakes when trying to justify high pricing through heavy science language. Claims like “DNA repair,” “cellular renewal therapy,” “epigenetic correction,” or “medical-grade” attract attention, but they also create exposure if used loosely. From a market positioning standpoint, the strongest US skincare brands tend to pair polished ingredient storytelling with restrained, consumer-legible claims. They sell aspiration and trust at the same time.

If your first US sales channel is Amazon, a dedicated Amazon Listing Audit can be valuable before go-live, because marketplace enforcement can be stricter and faster than many founders expect. If your broader challenge is organizing claim language, competitor references, and launch assets across teams, BrandVault and Industry Intel are useful for maintaining a current picture of US category movement rather than relying on outdated launch assumptions.

What to Watch in late 2026 and beyond

The next phase of US skincare compliance will likely be driven by three forces. First, ongoing FDA attention to intended use will continue to make claim wording the frontline issue for cosmetics. Second, online platforms and major retailers are expected to keep tightening their own content standards, particularly around medical-sounding claims, before-and-after imagery, and unsupported superlatives. Third, class-action activity around labeling and substantiation will remain a commercial risk for brands whose copy promises more than their evidence supports.

For skincare companies pursuing global expansion into the United States, the implication is clear: claims strategy should sit alongside formulation, channel selection, and competitive analysis as a core launch workstream. The winners will be brands that understand not only what ingredients are fashionable, but what stories those ingredients can legally and commercially sustain in the US market. A clean formula is not enough. A compelling claim is not enough. The launch advantage comes from aligning both with retailer realities, consumer expectations, and defensible regulatory compliance.

Brands that want to avoid expensive relabeling, listing edits, and stalled retail conversations should build a US-specific benchmark before launch. If you need that picture, request a personalized US Launch Intelligence Report or start with a free Brand Readiness Score to assess your claims, channel fit, and compliance readiness for the US skincare market.